Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.

ABSTRACT:

Background

Randomized controlled trials (RCT) established the mortality reduction by tocilizumab (Actemra), baricitinib (Olumiant), and sarilumab (Kevzara) in hospitalized COVID-19 patients. However, uncertainty remains about which treatment performs best in patients receiving corticosteroids.

Objectives

To estimate probabilities of noninferiority between baricitinib and sarilumab compared to tocilizumab in patients treated with corticosteroids.

Data sources

PubMed, Embase, Cochrane Library, and MedRxiv.

Study eligibility criteria

Eligible RCTs assigning hospitalized adults with COVID-19 treated with corticosteroids to tocilizumab or baricitinib or sarilumab versus standard of care or placebo (control).

Methods

Reviewers independently abstracted publishe

SUBMITTER: Albuquerque AM 

PROVIDER: S-EPMC9293401 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature